[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Cook et al., 2018 - Google Patents

TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17

Cook et al., 2018

View HTML
Document ID
13505404836127951327
Author
Cook A
Lee M
Saleh R
Khiew H
Christensen A
Achuthan A
Fleetwood A
Lacey D
Smith J
Förster I
Hamilton J
Publication year
Publication venue
JCI insight

External Links

Snippet

TNF and granulocyte macrophage-colony stimulating factor (GM-CSF) have proinflammatory activity and both contribute, for example, to rheumatoid arthritis pathogenesis. We previously identified a new GM-CSF→ JMJD3 demethylase→ interferon regulatory factor 4 (IRF4)→ …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Cook et al. TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17
Walsh et al. The emergence of the IL‐36 cytokine family as novel targets for inflammatory diseases
Sarkar et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa
Goropevšek et al. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus
Wang et al. Intricacies of TGF-β signaling in Treg and Th17 cell biology
Fu et al. TNFR2/14-3-3ε signaling complex instructs macrophage plasticity in inflammation and autoimmunity
Lopetuso et al. Opposing functions of classic and novel IL-1 family members in gut health and disease
Turnquist et al. IL-1β-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells
Wolk et al. The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis
Bas et al. CD14 is an acute-phase protein
Yoo et al. Placental growth factor regulates the generation of TH17 cells to link angiogenesis with autoimmunity
Martin et al. The NOD2 defect in Blau syndrome does not result in excess interleukin‐1 activity
Aparicio-Siegmund et al. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes
Agenes et al. Differential expression of regulator of G‐protein signalling transcripts and in vivo migration of CD4+ naive and regulatory T cells
Ng et al. Similarities and differences between IL11 and IL11RA1 knockout mice for lung fibro-inflammation, fertility and craniosynostosis
Stevanin et al. CD11b regulates the Treg/Th17 balance in murine arthritis via IL‐6
Ellinghaus et al. Dysregulated CD46 shedding interferes with Th1‐contraction in systemic lupus erythematosus
Villegas et al. Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis
Shashkova et al. Osteoclast-primed Foxp3+ CD8 T cells induce T-bet, eomesodermin, and IFN-γ to regulate bone resorption
JP7106604B2 (en) Methods and compositions for modulating TH-GM cell function
US20240156913A1 (en) Treatment and prevention of metabolic diseases
Mazzarella et al. Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions
Fujisawa et al. Involvement of the p38 MAPK pathway in IL‐13‐induced mucous cell metaplasia in mouse tracheal epithelial cells
Lenehan et al. Type 2 immunity is maintained during cancer-associated adipose tissue wasting
Veenbergen et al. Development and function of immune cells in an adolescent patient with a deficiency in the interleukin-10 receptor